Cargando…
Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
During the past decade, transdermal delivery systems (TDS) have become increasingly important for treating neurologic and psychiatric disorders. The rivastigmine patch was the first patch to be approved to treat Alzheimer’s disease (AD). The 9.5 mg/24 h patch has equal efficacy to the capsules and r...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761169/ https://www.ncbi.nlm.nih.gov/pubmed/19920911 |